Drug lookup | Fillwise

Sandoz Zolmitriptan ODT · DIN 02362996 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Zolmitriptan ODT · DIN 02362996 Manufacturer: Sandoz Canada Inc.; listing date 2011-09-15 Health Canada: Marketed since 2011-06-07 · brand SANDOZ ZOLMITRIPTAN ODT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Zolmitriptan ODT: Formulary list price $6.8625/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8625 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84797 · Verify on the e-Formulary ↗ (DIN 02362996)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02362996). DIN 02362996: Sandoz Zolmitriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id SDZ Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8625; ministry $6.8625 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84797

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: active shortage (reported 2024-06-12, estimated to end 2028-01-03, last updated 2026-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02362996

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Zolmitriptan OD · DIN 02342545 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Zolmitriptan OD · DIN 02342545 Manufacturer: Teva Canada Limited; listing date 2011-10-25 Health Canada: Marketed since 2011-06-07 · brand TEVA-ZOLMITRIPTAN OD · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Zolmitriptan OD: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82803 · Verify on the e-Formulary ↗ (DIN 02342545)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02342545). DIN 02342545: Teva-Zolmitriptan OD Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id TEV Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02342545 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82803

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: active shortage (reported 2022-03-18, last updated 2024-09-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342545

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zomig Rapimelt · DIN 02243045 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Savings card: innoviCares lists Zomig Rapimelt (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

Savings card: RxHelp ONE lists ZOMIG RAPIMELT (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)

1 brand, same coverage

Zomig Rapimelt · DIN 02243045 Manufacturer: AstraZeneca; listing date 2011-09-15 Health Canada: Marketed since 2023-01-12 · brand ZOMIG RAPIMELT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Xediton pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66907 · Verify on the e-Formulary ↗ (DIN 02243045)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243045). DIN 02243045: Zomig Rapimelt Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id AZC Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $17.7325; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243045 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66907

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633

Shortage status: resolved shortage (ended 2025-11-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243045

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Zolmitriptan · DIN 02481030 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Zolmitriptan · DIN 02481030 Manufacturer: Auro Pharma Inc.; listing date 2021-08-31 Health Canada: Marketed since 2020-03-18 · brand AURO-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Zolmitriptan: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97162 · Verify on the e-Formulary ↗ (DIN 02481030)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02481030). DIN 02481030: Auro-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id AUR Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481030 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97162

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2025-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481030

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Zolmitriptan · DIN 02421623 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Zolmitriptan · DIN 02421623 Manufacturer: Jamp Pharma Corporation; listing date 2014-07-30 Health Canada: Marketed since 2022-04-13 · brand JAMP-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90627 · Verify on the e-Formulary ↗ (DIN 02421623)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02421623). DIN 02421623: Jamp-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421623 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90627

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2026-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421623

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Zolmitriptan · DIN 02399458 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Zolmitriptan · DIN 02399458 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-06-26 Health Canada: Marketed since 2025-10-27 · brand MAR-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88433 · Verify on the e-Formulary ↗ (DIN 02399458)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02399458). DIN 02399458: Mar-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399458 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88433

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: active shortage (reported 2017-04-01, last updated 2018-12-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399458

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Zolmitriptan · DIN 02419521 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Zolmitriptan · DIN 02419521 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29 Health Canada: Marketed since 2021-12-02 · brand MINT-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90415 · Verify on the e-Formulary ↗ (DIN 02419521)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02419521). DIN 02419521: Mint-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id MIN Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419521 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90415

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2021-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02419521

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Zolmitriptan · DIN 02489392 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Zolmitriptan · DIN 02489392 Manufacturer: Nora Pharma; listing date 2023-01-31 Health Canada: Marketed since 2026-02-02 · brand NRA-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Zolmitriptan: Formulary list price $6.8600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97948 · Verify on the e-Formulary ↗ (DIN 02489392)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02489392). DIN 02489392: NRA-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id NRA Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8600; ministry $6.8600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97948

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2026-07-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489392

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Zolmitriptan · DIN 02421534 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Nat-Zolmitriptan · DIN 02421534 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30 Health Canada: Marketed since 2015-07-13 · brand NAT-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Natco pharma (canada) inc · schedule Prescription

Check this DIN again · Health Canada product record

Nat-Zolmitriptan: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90614 · Verify on the e-Formulary ↗ (DIN 02421534)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02421534). DIN 02421534: Nat-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id NAT Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421534 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90614

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2026-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421534

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Zolmitriptan · DIN 02362988 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Zolmitriptan · DIN 02362988 Manufacturer: Sandoz Canada Inc.; listing date 2011-09-15 Health Canada: Marketed since 2011-06-07 · brand SANDOZ ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Zolmitriptan: Formulary list price $6.8586/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8586 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84796 · Verify on the e-Formulary ↗ (DIN 02362988)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02362988). DIN 02362988: Sandoz Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8586; ministry $6.8586 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362988 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84796

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: active shortage (reported 2025-06-09, estimated to end 2028-01-03, last updated 2026-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02362988

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Zolmitriptan · DIN 02313960 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Zolmitriptan · DIN 02313960 Manufacturer: Teva Canada Limited; listing date 2011-10-25 Health Canada: Marketed since 2011-06-07 · brand TEVA-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79948 · Verify on the e-Formulary ↗ (DIN 02313960)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02313960). DIN 02313960: Teva-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313960 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79948

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: resolved shortage (ended 2023-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313960

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zomig · DIN 02238660 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

How long EAP takes

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Savings card: innoviCares lists Zomig (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

Savings card: RxHelp ONE lists ZOMIG (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)

1 brand, same coverage

Zomig · DIN 02238660 Manufacturer: AstraZeneca; listing date 2011-09-15 Health Canada: Marketed since 2023-01-12 · brand ZOMIG · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Xediton pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62089 · Verify on the e-Formulary ↗ (DIN 02238660)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02238660). DIN 02238660: Zomig Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id AZC Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $17.7325; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238660 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62089

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583

Shortage status: resolved shortage (ended 2025-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238660

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Zolmitriptan Rapid · DIN 02381575 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2019-02-20 · checked 2026-09-02 · What does dormant mean?

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Zolmitriptan Rapid · DIN 02381575 Manufacturer: Apotex Inc.; listing date 2012-12-21 Health Canada: Dormant since 2019-02-20 · brand APO-ZOLMITRIPTAN RAPID · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Zolmitriptan Rapid: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86742 · Verify on the e-Formulary ↗ (DIN 02381575)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02381575). DIN 02381575: Apo-Zolmitriptan Rapid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id APX Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381575 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86742

Interchangeable products

Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381575

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2019-02-20 — choose a marketed DIN from the same-category list.

Jamp-Zolmitriptan ODT · DIN 02428237 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2021-07-29 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Zolmitriptan ODT · DIN 02428237 Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28 Health Canada: Dormant since 2021-07-29 · brand JAMP-ZOLMITRIPTAN ODT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Zolmitriptan ODT: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91271 · Verify on the e-Formulary ↗ (DIN 02428237)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02428237). DIN 02428237: Jamp-Zolmitriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id JPC Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428237 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91271

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: active shortage (reported 2018-01-08, last updated 2021-07-30) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428237

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2021-07-29 — choose a marketed DIN from the same-category list.

Septa-Zolmitriptan-ODT · DIN 02428474 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2018-07-23 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Septa-Zolmitriptan-ODT · DIN 02428474 Manufacturer: Septa Pharmaceuticals Inc.; listing date 2014-12-18 Health Canada: Dormant since 2018-07-23 · brand SEPTA-ZOLMITRIPTAN-ODT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Septa pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Septa-Zolmitriptan-ODT: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91294 · Verify on the e-Formulary ↗ (DIN 02428474)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02428474). DIN 02428474: Septa-Zolmitriptan-ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id SET Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428474 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91294

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: active shortage (reported 2017-06-27, last updated 2019-08-01) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428474

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2018-07-23 — choose a marketed DIN from the same-category list.

Zolmitriptan ODT · DIN 02442671 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-09-29 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Zolmitriptan ODT · DIN 02442671 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Dormant since 2025-09-29 · brand ZOLMITRIPTAN ODT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Zolmitriptan ODT: Formulary list price $6.8633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92701 · Verify on the e-Formulary ↗ (DIN 02442671)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02442671). DIN 02442671: Zolmitriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id SAI Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8633; ministry $6.8633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442671 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92701

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Mint-Zolmitriptan ODT · DIN 02419513 · $6.8625 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: active shortage (reported 2024-09-11, last updated 2025-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442671

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-09-29 — choose a marketed DIN from the same-category list.

Apo-Zolmitriptan · DIN 02380951 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2019-08-02 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Zolmitriptan · DIN 02380951 Manufacturer: Apotex Inc.; listing date 2012-05-29 Health Canada: Dormant since 2019-08-02 · brand APO-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86671 · Verify on the e-Formulary ↗ (DIN 02380951)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02380951). DIN 02380951: Apo-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380951 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86671

Interchangeable products

Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: discontinued (2018-01-26, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380951

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2019-08-02 — choose a marketed DIN from the same-category list.

Jamp Zolmitriptan · DIN 02477106 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2023-07-31 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Zolmitriptan · DIN 02477106 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Dormant since 2023-07-31 · brand JAMP ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96780 · Verify on the e-Formulary ↗ (DIN 02477106)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02477106). DIN 02477106: Jamp Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477106 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96780

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: active shortage (reported 2022-02-09, estimated to end 2023-12-31, last updated 2023-06-22) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477106

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2023-07-31 — choose a marketed DIN from the same-category list.

Zolmitriptan · DIN 02442655 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-07-23 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Zolmitriptan · DIN 02442655 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Dormant since 2026-07-23 · brand ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Zolmitriptan: Formulary list price $6.8583/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8583 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92700 · Verify on the e-Formulary ↗ (DIN 02442655)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02442655). DIN 02442655: Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8583; ministry $6.8583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442655 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92700

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 CCP-Zolmitriptan · DIN 02458780 · $6.8586 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: active shortage (reported 2025-04-14, last updated 2025-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442655

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

Mint-Zolmitriptan ODT · DIN 02419513 · 2.5mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-19 — choose a marketed DIN from the same-category list.Discontinued 2017-06-19 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-19 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-06-19 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Zolmitriptan ODT · DIN 02419513 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-06-26 Health Canada: Cancelled post market since 2017-06-19 · brand MINT-ZOLMITRIPTAN ODT · ATC N02CC03 ZOLMITRIPTAN · form Tablet (orally-disintegrating) · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Zolmitriptan ODT: Formulary list price $6.8625/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8625 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90414 · Verify on the e-Formulary ↗ (DIN 02419513)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02419513). DIN 02419513: Mint-Zolmitriptan ODT Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200015; group id 546; item number 1477; lccId None; manufacturer id MIN Source form: Orally Disintegrating Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8625; ministry $6.8625 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419513 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90414

Interchangeable products

Apo-Zolmitriptan Rapid · DIN 02381575 · $6.8633 Jamp-Zolmitriptan ODT · DIN 02428237 · $6.8633 Sandoz Zolmitriptan ODT · DIN 02362996 · $6.8625 Septa-Zolmitriptan-ODT · DIN 02428474 · $6.8633 Teva-Zolmitriptan OD · DIN 02342545 · $6.8633 Zolmitriptan ODT · DIN 02442671 · $6.8633 Zomig Rapimelt · DIN 02243045 · $6.8633

Shortage status: discontinued (2017-06-30, reported by MINT PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02419513

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2017-06-19 — choose a marketed DIN from the same-category list.

CCP-Zolmitriptan · DIN 02458780 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued 2023-08-03 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Zomig; DOSAGE FORM/ STRENGTH: 2.5 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Zolmitriptan Brand(s): Zomig DOSAGE FORM/ STRENGTH: 2.5 mg tablet Brand(s): Zomig Rapimelt DOSAGE FORM/ STRENGTH: 2.5 mg dispersible tablet For the treatment of migraines with or without aura in patients who have failed an adequate trial of or experienced intolerance to all other oral triptans considered under the Exceptional Access Program. Duration of Approvals: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. 218 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 218, record 128, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

CCP-Zolmitriptan · DIN 02458780 Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2019-07-31 Health Canada: Cancelled post market since 2023-08-03 · brand CCP-ZOLMITRIPTAN · ATC N02CC03 ZOLMITRIPTAN · form Tablet · route Oral · ingredients ZOLMITRIPTAN 2.5 MG · company Cellchem pharmaceuticals inc. · schedule Prescription

Check this DIN again · Health Canada product record

CCP-Zolmitriptan: Formulary list price $6.8586/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8586 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94593 · Verify on the e-Formulary ↗ (DIN 02458780)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02458780). DIN 02458780: CCP-Zolmitriptan Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 289200013; group id 546; item number 1478; lccId None; manufacturer id CCP Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.8586; ministry $6.8586 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458780 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94593

Interchangeable products

Apo-Zolmitriptan · DIN 02380951 · $6.8583 Auro-Zolmitriptan · DIN 02481030 · $6.8633 Jamp Zolmitriptan · DIN 02477106 · $6.8583 Jamp-Zolmitriptan · DIN 02421623 · $6.8583 Mar-Zolmitriptan · DIN 02399458 · $6.8583 Mint-Zolmitriptan · DIN 02419521 · $6.8583 NRA-Zolmitriptan · DIN 02489392 · $6.8600 Nat-Zolmitriptan · DIN 02421534 · $6.8633 Sandoz Zolmitriptan · DIN 02362988 · $6.8586 Teva-Zolmitriptan · DIN 02313960 · $6.8583 Zolmitriptan · DIN 02442655 · $6.8583 Zomig · DIN 02238660 · $6.8633

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458780

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Look up one drug

ZOLMITRIPTAN

Sandoz Zolmitriptan ODT · DIN 02362996 · 2.5mg · Orally Disintegrating tablet

Teva-Zolmitriptan OD · DIN 02342545 · 2.5mg · Orally Disintegrating tablet

Zomig Rapimelt · DIN 02243045 · 2.5mg · Orally Disintegrating tablet

Auro-Zolmitriptan · DIN 02481030 · 2.5mg · tablet

Jamp-Zolmitriptan · DIN 02421623 · 2.5mg · tablet

Mar-Zolmitriptan · DIN 02399458 · 2.5mg · tablet

Mint-Zolmitriptan · DIN 02419521 · 2.5mg · tablet

NRA-Zolmitriptan · DIN 02489392 · 2.5mg · tablet

Nat-Zolmitriptan · DIN 02421534 · 2.5mg · tablet

Sandoz Zolmitriptan · DIN 02362988 · 2.5mg · tablet

Teva-Zolmitriptan · DIN 02313960 · 2.5mg · tablet

Zomig · DIN 02238660 · 2.5mg · tablet

Apo-Zolmitriptan Rapid · DIN 02381575 · 2.5mg · Orally Disintegrating tablet

Jamp-Zolmitriptan ODT · DIN 02428237 · 2.5mg · Orally Disintegrating tablet

Septa-Zolmitriptan-ODT · DIN 02428474 · 2.5mg · Orally Disintegrating tablet

Zolmitriptan ODT · DIN 02442671 · 2.5mg · Orally Disintegrating tablet

Apo-Zolmitriptan · DIN 02380951 · 2.5mg · tablet

Jamp Zolmitriptan · DIN 02477106 · 2.5mg · tablet

Zolmitriptan · DIN 02442655 · 2.5mg · tablet

Mint-Zolmitriptan ODT · DIN 02419513 · 2.5mg · Orally Disintegrating tablet

CCP-Zolmitriptan · DIN 02458780 · 2.5mg · tablet

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

ELETRIPTAN

FROVATRIPTAN SUCCINATE

NARATRIPTAN HYDROCHLORIDE

RIZATRIPTAN

SUMATRIPTAN SUCCINATE

PIZOTYLINE

ATOMOXETINE HCL

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

ACAMPROSATE CALCIUM

ENTACAPONE

DIMETHYL FUMARATE

Availability

Prepare an Exceptional Access request

Zolmitriptan (Zomig)

Other review policies